CSRWire - Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
Moody's upgrades Teva's rating outlook - גלובס
Credit Trends: The Media And Entertainment Sector Shows High Downgrade Potential | S&P Global Ratings
Teva Reports Third Quarter 2021 Financial Results
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report | Business Wire
Teva woes deepen as Fitch cuts credit rating to junk | The Times of Israel
1 Healthcare Stock to Avoid in 2022 | The Motley Fool
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
Plaintiffs Say Teva Willfully Withheld Opioid Audit Report - Legal Reader
Teva Faces Rocky Path to Recovery After Debt | Fortune
Credit Trends: Downgrade Potential Rises To All-Time High On Sharp, Deep Economic Slowdown | S&P Global Ratings
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
Teva Ramping Up Asset Sales to Preserve Credit Rating - TheStreet
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024 | Business Wire
Teva Pharmaceuticals - Wikipedia
Teva Pharmaceuticals has acquired success with Actavis Generics | World Finance
Why Teva's Stock Could Crash Another 50% | BioSpace
S&P downgrades Teva, pushing credit rating further into junk territory - Business - Haaretz.com
Credit Rating Process | A Complete Beginner's Guide
S&P Global Ratings downgrades Local Currency LT credit rating of Teva Pharmaceutical Industries to "BB-"; outlook stable
Teva Pharmaceutical Industries (TEVA) Stock Price, News & Info | The Motley Fool
Teva May Have to Make Difficult Capital Allocation Decisions Under Pressure From Potential Generic Competition, Deleveraging Goals - Reorg
